TrialThe Journal of infectious diseases2025

A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants.

Shabir A Madhi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.